Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HA1 | P13674 | 3/20 | 0.58 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.58 |
| ▸ | KMO | O15229 | 2/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | LDHA | P00338 | 3/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | KDM5A | P29375 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.47 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 2/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069893 | 0.88 | P4HA1 (0.58) | P4HA1P4HTMKMODHODHLDHA | |
| SCHEMBL4653904 | 0.85 | P4HA1 (0.54) | P4HA1P4HTMKMODHODHLDHA | |
| SCHEMBL1543497 | 0.83 | P4HA1 (0.56) | P4HA1P4HTMLDHAKDM4CNPC1 | |
| SCHEMBL9607067 | 0.82 | DHODH (0.47) | KMODHODHKDM4AKDM5AKDM4C | |
| SCHEMBL27605098 | 0.81 | LDHA (0.51) | P4HA1P4HTMKMODHODHLDHA | |
| SCHEMBL2070102 | 0.81 | LDHA (0.62) | P4HA1P4HTMDHODHLDHANPC1 | |
| SCHEMBL30540118 | 0.79 | KMO (0.47) | KMODHODHNPC1FEN1MEN1 | |
| SCHEMBL19248543 | 0.79 | KMO (0.47) | KMODHODHNPC1FEN1MEN1 | |
| SCHEMBL2120167 | 0.79 | P4HA1 (0.46) | P4HA1P4HTMKMODHODHLDHA | |
| SCHEMBL3501871 | 0.77 | DHODH (0.44) | KMODHODHNPC1RXFP1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608617-B1 | MUSCARINIC AGONISTS | LILLY CO ELI (US) | 2013-01-09 | — | — | EP | disclosed |
| EP-1606289-B1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LTD (GB) | 2009-12-02 | — | — | EP | disclosed |
| US-7531558-B2 | e.g. 6-(4-Fluorophenyl)-2-methyl-N-(2-methylbenzothiazol-5-yl)nicotinamide; vanilloid (capsaicin) receptor modulator; analgesic; chronic, neuropathic, postoperative, postrheumatoid arthritic, osteoarthritic, back, cancer, dental pain, algesia, neuralgia, migraine, neuropathies, ischaemia | GLAXO GROUP LIMITED (GB) | 2009-05-12 | — | — | US | disclosed |
| US-7326731-B2 | Muscarinic agonists | ELI LILLY AND COMPANY (US) | 2008-02-05 | — | — | US | disclosed |
| EP-1644320-B1 | INDANE DERIVATES AS MUSCARINIC RECEPTOR AGONISTS | LILLY CO ELI (US) | 2008-01-16 | — | — | EP | disclosed |
| US-7265246-B2 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | ELI LILLY AND COMPANY (US) | 2007-03-15 | — | — | US | disclosed |
| US-20060148855-A1 | Carboxamide derivatives | GLAXO GROUP LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1606289-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004072069-A1 | CARBOXAMIDE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148855-A1 | Carboxamide derivatives | CNR2, CNR1, SUCNR1 | P4HA1 1934/4885P4HTM 2607/4885KMO 2640/4885 |
| US-20070060587-A1 | Indane derivates as muscarinic receptor agonists | CHRM1, CHRM3, CHRM2 | P4HA1 3159/4885P4HTM 2222/4885KMO 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.